ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO0499

Healthcare Resource Utilization and Costs in a DAPA-CKD-Like Population Using a Contemporary US Healthcare Cohort

Session Information

Category: CKD (Non-Dialysis)

  • 2101 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention


  • Olufade, Tope, AstraZeneca, Wilmington, North Carolina, United States
  • Lamerato, Lois, Henry Ford Health System, Detroit, Michigan, United States
  • Garcia Sanchez, Juan Jose, AstraZeneca UK Ltd, Cambridge, Cambridgeshire, United Kingdom
  • Jiang, Like, AstraZeneca, Wilmington, North Carolina, United States
  • Huang, Joanna C., AstraZeneca, Wilmington, North Carolina, United States
  • Nolan, Stephen, AstraZeneca UK Ltd, Cambridge, Cambridgeshire, United Kingdom

The DAPA-CKD Trial is the first SGLT-2i renal outcome trial to test the efficacy and safety of an SGLT-2i, dapagliflozin, in patients with diagnosed CKD with and without T2D.
The objective of this study is to assess the healthcare resource utilization and cost in a “DAPA-CKD-like population” (eGFR 25-75ml/min/1.73m2 and UACR 200-5000mg/g) using a contemporary US healthcare system.


Data from the Henry Ford Health System (HFHS) were used to identify patients with CKD stages 2 through 4 between 2006 and 2016 (based on eGFR labs) and patients were followed through 2018. Patients with no confirmatory eGFR > 90 days from index date, death within 30 days, history of renal transplant, and evidence of renal replacement therapy, or progression to CKD stage 5 during the baseline period (6 months pre or post index date) were excluded.
Cumulative primary and secondary utilization was evaluated for all patients during the follow-up time. Annual utilization rates are the total observed utilization divided by follow-up time. Billing records with HFHS were used to estimate costs.


6,557 patients (mean age 62.9 years, 46.2% male) met the eligibility criteria and are included in the study cohort. The population was stratified by UACR (0-<30, 30–199, 200–5,000mg/g). The DAPA-CKD-like population (200-5000mg/g) was associated with significantly higher annualized per-patient healthcare costs, $39,222/yr (UACR 200-5000mg/g) vs. $19,547/yr (UACR <30mg/g). Persons in the highest UACR category were almost three times more likely to have a hospital admission compared to the lowest (rates 0.55/year vs. 0.20/year, respectively; see Table 1).


This analysis of a contemporary US healthcare system demonstrated that there exists a high disease burden in the DAPA-CKD-like population as seen by the substantial increase in healthcare resource utilization and costs compared to other cohorts of patients with a lower UACR. These results highlight the need for innovative therapies to improve patient outcomes in this high risk population.


  • Commercial Support